Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc.（MDGL）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · MDGL · 截至 2026年6月8日
活动摘要
买入笔数
54
P-Purchase only
卖出笔数
245
近12个月
买卖比
0.22
Buy/Sell (by trades)
整体情绪
Madrigal Pharmaceuticals, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
MDGL 季度内部人买卖趋势
MDGL 内幕交易卖出 · MDGL 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · MDGL CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
MDGL 高管卖出股份 · MDGL 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jun 1, 2026 | Soergel David Chief Medical Officer | Sale | 1,042 | $517K | Form 4 |
| May 22, 2026 | Levy Richard S Director | Sale | 40 | $20K | Form 4 |
| May 22, 2026 | Levy Richard S Director | Sale | 320 | $163K | Form 4 |
| May 22, 2026 | Levy Richard S Director | Sale | 151 | $77K | Form 4 |
| May 22, 2026 | Levy Richard S Director | Sale | 610 | $312K | Form 4 |
| May 22, 2026 | Levy Richard S Director | Sale | 439 | $225K | Form 4 |
| May 22, 2026 | Levy Richard S Director | Sale | 40 | $21K | Form 4 |
| May 22, 2026 | Levy Richard S Director | Sale | 343 | $177K | Form 4 |
| May 22, 2026 | Levy Richard S Director | Sale | 657 | $339K | Form 4 |
| May 22, 2026 | Levy Richard S Director | Sale | 723 | $374K | Form 4 |
| May 22, 2026 | Levy Richard S Director | Sale | 1,497 | $775K | Form 4 |
| May 22, 2026 | Levy Richard S Director | Sale | 782 | $406K | Form 4 |
| May 22, 2026 | Levy Richard S Director | Sale | 80 | $42K | Form 4 |
| May 18, 2026 | Soergel David Chief Medical Officer | Sale | 844 | $435K | Form 4 |
| Mar 4, 2026 | Dier Mardi EVP and CFO | Award | 5,215 | — | Form 4 |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 646 | $279K | Form 4 |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 40 | $17K | Form 4 |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 420 | $179K | Form 4 |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 80 | $34K | Form 4 |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 160 | $69K | Form 4 |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 40 | $17K | Form 4 |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 120 | $52K | Form 4 |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 116 | $50K | Form 4 |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 160 | $69K | Form 4 |
| Mar 6, 2026 | Dier Mardi EVP and CFO | Sale | 80 | $35K | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 MDGL 内幕交易
MDGL 内幕交易
Madrigal Pharmaceuticals, Inc.（MDGL）内幕交易数据来源于公司内部人（包括FRIEDMAN PAUL A (Director), Levy Richard S (Director), Dier Mardi (EVP and CFO)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。MDGL内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Madrigal Pharmaceuticals, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
MDGL 内幕交易 · 5个问题Madrigal Pharmaceuticals, Inc.（MDGL）的内部人包括高管和董事，如FRIEDMAN PAUL A (Director), Levy Richard S (Director), Dier Mardi (EVP and CFO)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026